Real-world recurrence patterns and patient outcomes after 2 years of pembrolizumab immunotherapy in advanced non-small cell lung cancer.

Clinical Lung Cancer · Elsevier

The publisher did not provide an abstract — full text is available via the link below.

Read at publisher →

Similar articles